- Alnylam Issues 2023 Corporate Responsibility Report
- Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
- Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
- Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
- Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
- Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
- Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
- Alnylam to Webcast Presentations at Upcoming March Investor Conferences
More ▼
Key statistics
As of last trade Alnylam Pharmaceuticals Inc (ALNY:NSQ) traded at 149.89, 5.57% above its 52-week low of 141.98, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 149.30 |
---|---|
High | 150.78 |
Low | 147.78 |
Bid | 149.77 |
Offer | 150.07 |
Previous close | 149.40 |
Average volume | 531.72k |
---|---|
Shares outstanding | 126.49m |
Free float | 125.97m |
P/E (TTM) | -- |
Market cap | 18.96bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of May 20 2024 20:37 BST.
More ▼